WAVE Life Sciences Ltd.

WVE Healthcare Biotechnology

WAVE Life Sciences Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42.7 million, down 60.5% from fiscal 2024.

Revenue
+73.0%
EPS
+5.25%
Free cash flow
−33.9%

Quarter to September 2026, against a year earlier

3.36 0.14 +4.35%
Market cap
$635.1M
P/E
0.0×
Fwd P/E
−3.2×
Dividend yield
—
F-score
3/9
Altman Z
11.34
Beneish M
−2.44
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
67.10 20.21 18.13 10.65
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(84.88) (24.37) (22.12) (12.56)
P/B ratio
5.53 2.84 2.61 1.88
EV/Sales
53.01 12.63 10.63 4.58
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(12.03) (4.90) (3.60) (1.56)
Current Ratio
6.47 11.26 9.99 8.38
Net Debt/EBITDA
11.11 18.78 6.87 6.76
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(7.18%) (14.62%) (18.76%) (29.01%)
Free Cash Flow Yield
(6.56%) (12.75%) (16.30%) (27.58%)
Free Cash Flow per Share
(0.20) (0.30) (0.27) (0.29)
Book value per Share
3.07 2.56 2.22 1.97
Free Cash Flow
(33.77) (59.99) (54.47) (60.16)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026